प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
Sana Biotechnology: UP421 का 12-सप्ताह NEJM डेटा दर्शाता है कि HIP आइलेट कोशिकाएं T1D में जीवित रहकर काम करती हैं
The 8-K reports positive 12-week results from the UP421 investigator-sponsored study published in NEJM, confirming that hypoimmune-modified allogeneic islet cells survive, evade immune detection, and produce insulin without immunosuppression in a type 1 diabetes patient. These data, together with recent FDA INTERACT feedback, increase regulatory confidence for the related SC451 iPSC-derived program and support an IND filing as early as 2026.
मुख्य तथ्य
स्रोत का अंश
EX-99.1 2 sana-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan, and path to filing SC451 Investigational New Drug Application (IND) as early as 2026 The New England Journal of Medicine published positive 12-week clinical results of ongoing type 1 diabetes study with UP421, which demonstrate that Sana’s hypoimmune-modified pancreatic islet cells are safe and well-tolerated, survive, evade detection by the immune system, and produce insulin in the patient Next-generation in vivo CAR T product candidate, SG293, demonstr
इस संपत्ति पर और
उल्लेखनीय
10 अग॰ 2026
08:09 pm
SANASana BiotechnologySana Biotechnology: EASD 2026 में 2 अक्टूबर को UP421 डेटा
उल्लेखनीय
14 जन॰ 2026
05:45 pm
SANASana BiotechnologySana Biotechnology के 2026 लक्ष्य: SC451 की IND फाइलिंग और SG293 का पहला मानव परीक्षण डेटा